4SC AG — Capital/Financing Update 2006

May 11, 2006

News Details

Ad-hoc | 11 May 2006 22:57

4SC completes capital increase

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Ad hoc announcement §15 of the Securities Trading Act (WpHG) Capital increase 4SC completes capital increase Planegg-Martinsried, 11 May 2006 – With the approval of the Supervisory Board, the Management Board of the Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) has resolved as well as placed completely a capital increase with 0.9 million euros of authorised capital, thus reacting to the demand among institutional investors. Shareholders were precluded from exercising a right of subscription as stipulated in §§ 203 Paragraph 1, 186 Paragraph 3 Item 4 of the Shareholders Act (AktG). A total of 931,288 4SC AG shares were placed with institutional investors at a price of 4.65 euros per share. 4SC AG achieved gross proceeds of 4.3 million euros from the transaction, which the company will use to efficiently develop its project pipeline and, in particular, press ahead with its projects in the clinical development stage. As a result of the capital increase, 4SC AG’s subscribed capital increases from 10.5 million euros to 11.5 million euros. Following the capital increase, the free float increases to 20.69 percent of the share capital. The Conrad Hinrich Donner Bank and M.M. Warburg attended to the transaction. End of the ad hoc report About 4SC AG 4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 53, the company develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases (‘proof of concept’) and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. The pipeline currently has five projects, the first of which, on the treatment of rheumatoid arthritis, has successfully completed clinical phase I. Preparations for the conduct of the IIa clinical phase are well under way. A further one to two other product candidates should go into clinical development in 2006. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues. Legal note This document may contain forecasts, estimates and assumptions concerning business plans and goals, products and services and future results or assumptions based on or relating to them. Any statements about the future are subject to risks and uncertainty that are not predictable and are beyond the control of 4SC AG. Many factors may cause the actual results to differ substantially from the results contained in such statements about the future. For further information, please contact us at: Bettina von Klitzing Manager Investor Relations und Public Relations 4SC AG Tel.: +49 (0) 89 70 07 63 – 0 Bettina.von.klitzing@4sc.com On behalf of 4SC AG: Regine Petzsch komm.passion Schumacher´s AG Tel.: +49 (0) 89 48 92 72 – 40 Regine.Petzsch@komm-passion.de (c)DGAP 11.05.2006 ————————————————————————— Language: English Issuer: 4SC AG Am Klopferspitz 19a 82152 Martinsried Deutschland Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 email: public@4sc.com WWW: www.4sc.de ISIN: DE0005753818 WKN: 575381 indices: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, München, Stuttgart End of News DGAP News-Service —————————————————————————